CN111670050A - 用于治疗睡眠呼吸暂停的方法和组合物 - Google Patents

用于治疗睡眠呼吸暂停的方法和组合物 Download PDF

Info

Publication number
CN111670050A
CN111670050A CN201980010884.XA CN201980010884A CN111670050A CN 111670050 A CN111670050 A CN 111670050A CN 201980010884 A CN201980010884 A CN 201980010884A CN 111670050 A CN111670050 A CN 111670050A
Authority
CN
China
Prior art keywords
oxybutynin
composition
nri
atomoxetine
reuptake inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980010884.XA
Other languages
English (en)
Chinese (zh)
Inventor
L·G·米勒
B·沃尔
W·J·伦斯曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epuning Delaware
Original Assignee
Epuning Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epuning Delaware filed Critical Epuning Delaware
Priority to CN202410467832.8A priority Critical patent/CN118384147A/zh
Publication of CN111670050A publication Critical patent/CN111670050A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201980010884.XA 2018-01-30 2019-01-30 用于治疗睡眠呼吸暂停的方法和组合物 Pending CN111670050A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410467832.8A CN118384147A (zh) 2018-01-30 2019-01-30 用于治疗睡眠呼吸暂停的方法和组合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
US62/623,892 2018-01-30
PCT/US2019/015781 WO2019152475A1 (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410467832.8A Division CN118384147A (zh) 2018-01-30 2019-01-30 用于治疗睡眠呼吸暂停的方法和组合物

Publications (1)

Publication Number Publication Date
CN111670050A true CN111670050A (zh) 2020-09-15

Family

ID=65441079

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201980010884.XA Pending CN111670050A (zh) 2018-01-30 2019-01-30 用于治疗睡眠呼吸暂停的方法和组合物
CN202410467832.8A Pending CN118384147A (zh) 2018-01-30 2019-01-30 用于治疗睡眠呼吸暂停的方法和组合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410467832.8A Pending CN118384147A (zh) 2018-01-30 2019-01-30 用于治疗睡眠呼吸暂停的方法和组合物

Country Status (27)

Country Link
US (6) US11911351B2 (https=)
EP (2) EP3746126B1 (https=)
JP (3) JP7422666B2 (https=)
KR (2) KR102874891B1 (https=)
CN (2) CN111670050A (https=)
AU (2) AU2019214891B2 (https=)
BR (1) BR112020015316A2 (https=)
CA (1) CA3089712A1 (https=)
DK (1) DK3746126T3 (https=)
EA (1) EA202091597A1 (https=)
ES (1) ES2991425T3 (https=)
FI (1) FI3746126T3 (https=)
HR (1) HRP20241412T1 (https=)
HU (1) HUE068505T2 (https=)
IL (1) IL276247A (https=)
LT (1) LT3746126T (https=)
MA (1) MA52861B1 (https=)
MD (1) MD3746126T2 (https=)
MX (2) MX2020008086A (https=)
PL (1) PL3746126T3 (https=)
PT (1) PT3746126T (https=)
RS (1) RS66104B1 (https=)
SG (1) SG11202007226UA (https=)
SI (1) SI3746126T1 (https=)
SM (1) SMT202400400T1 (https=)
UA (1) UA129618C2 (https=)
WO (1) WO2019152475A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
CN118557736A (zh) 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
WO2022069250A1 (en) 2020-09-30 2022-04-07 Koninklijke Philips N.V. Methods and systems for performing dose titration
AU2022231133A1 (en) * 2021-03-04 2023-09-21 Apnimed, Inc. (Delaware) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
WO2022204228A1 (en) * 2021-03-24 2022-09-29 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
EP4334281A1 (en) 2021-05-04 2024-03-13 Apnimed, Inc. (Delaware) Solid forms of (r)-oxybutynin d-malate
US20240277719A1 (en) * 2021-06-17 2024-08-22 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
KR20240124995A (ko) 2021-12-22 2024-08-19 바이엘 악티엔게젤샤프트 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물
CA3259602A1 (en) 2021-12-22 2023-06-29 Bayer Aktiengesellschaft Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20250000641A (ko) * 2023-06-27 2025-01-03 주식회사 아스트로젠 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2003039436A2 (es) * 2001-11-06 2003-05-15 Osmotica Costa Rica Sociedad Anonima Composiciones farmaceuticas que contienen oxibutinina

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (https=) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
DE69636393T2 (de) 1995-10-24 2006-12-07 Grünenthal GmbH Montirelin zur verhinderung der schlafapnoe
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
JP2006524708A (ja) 2003-04-25 2006-11-02 インディヴァス ファーマシューティカルズ，インコーポレーテッド 塩化トロスピウムの投与により連続睡眠を促進するための方法
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1827450A4 (en) 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
US20080009538A1 (en) 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence
CA2603920A1 (en) 2005-04-15 2006-10-26 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20070021927A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2142183A2 (en) 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US20090048233A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination
AR069875A1 (es) 2007-12-21 2010-02-24 Eurand Inc Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
EP2552205A4 (en) 2010-04-01 2014-01-01 Theravida Inc PROCESS FOR INCREASING SLEEP QUALITY
JP2014503593A (ja) 2011-01-28 2014-02-13 ファンタスティック・メディカル・リサーチ・インスティテュート・エルエルシー 閉塞性睡眠時無呼吸を処置するための方法
JP2012176958A (ja) 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
DK2964185T3 (da) 2013-03-05 2022-02-14 Requis Pharmaceuticals Inc Præparater til behandlingen af søvnrelaterede luftvejslidelser
US20170304286A1 (en) 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
MX373319B (es) 2015-04-27 2020-06-13 Arena Pharm Inc Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.
ES2925951T3 (es) 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
WO2017031319A1 (en) 2015-08-18 2017-02-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
GEAP202416602A (en) * 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
AR114350A1 (es) 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital Terapia genética para la distrofia muscular de cinturas del tipo 2c
CN118557736A (zh) 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001062236A2 (en) * 2000-02-24 2001-08-30 Pharmacia & Upjohn Company New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2003039436A2 (es) * 2001-11-06 2003-05-15 Osmotica Costa Rica Sociedad Anonima Composiciones farmaceuticas que contienen oxibutinina

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRIGHAM AND WOMEN’S HOSPITAL: "Atomoxetine and Oxybutynin in Obstructive Sleep Apnea (ATOSA)", 《CLINICALTRIALS.GOV.ARCHIVE HTTPS://CLINICALTRIALS.GOV/CT2/HISTORY/NCT02908529?V_3=VIEW#STUDYPAGETOP》 *
MELINDA WUEST: "Oxybutynin", 《XPHARM: THE COMPREHENSIVE PHARMACOLOGY REFERENCE》 *

Also Published As

Publication number Publication date
US11911351B2 (en) 2024-02-27
RS66104B1 (sr) 2024-11-29
ES2991425T3 (es) 2024-12-03
KR20200115598A (ko) 2020-10-07
KR20250156197A (ko) 2025-10-31
MX2024001713A (es) 2024-02-20
EP4445951A3 (en) 2025-01-08
EP3746126B1 (en) 2024-07-31
CN118384147A (zh) 2024-07-26
JP2021516218A (ja) 2021-07-01
US20220378724A1 (en) 2022-12-01
JP2025159230A (ja) 2025-10-17
SMT202400400T1 (it) 2024-11-15
KR102874891B1 (ko) 2025-10-21
EP4445951A2 (en) 2024-10-16
HRP20241412T1 (hr) 2024-12-20
LT3746126T (lt) 2024-10-25
US20250186371A1 (en) 2025-06-12
UA129618C2 (uk) 2025-06-18
BR112020015316A2 (pt) 2020-12-08
US20210038541A1 (en) 2021-02-11
AU2019214891A1 (en) 2020-08-20
WO2019152475A1 (en) 2019-08-08
EA202091597A1 (ru) 2020-10-22
SI3746126T1 (sl) 2025-01-31
US20240390299A1 (en) 2024-11-28
MA52861A (fr) 2021-05-05
MA52861B1 (fr) 2024-09-30
JP2023181322A (ja) 2023-12-21
HUE068505T2 (hu) 2024-12-28
MX2020008086A (es) 2021-02-15
US20240156753A1 (en) 2024-05-16
IL276247A (en) 2020-09-30
AU2024227631A1 (en) 2024-11-14
SG11202007226UA (en) 2020-08-28
PT3746126T (pt) 2024-10-21
EP3746126A1 (en) 2020-12-09
FI3746126T3 (fi) 2024-10-10
AU2019214891B2 (en) 2024-08-01
US20260027070A1 (en) 2026-01-29
JP7422666B2 (ja) 2024-01-26
CA3089712A1 (en) 2019-08-08
PL3746126T3 (pl) 2024-12-16
DK3746126T3 (da) 2024-10-07
MD3746126T2 (ro) 2024-12-31
NZ766673A (en) 2025-08-29

Similar Documents

Publication Publication Date Title
US20260007618A1 (en) Methods and compositions for treating sleep apnea
US20250186371A1 (en) Methods and compositions for treating sleep apnea
US20250114321A1 (en) Methods and compositions for treating sleep apnea
HK40117857A (en) Methods and compositions for treating sleep apnea
HK40031779B (en) Methods and compositions for treating sleep apnea or simple snoring
HK40031779A (en) Methods and compositions for treating sleep apnea or simple snoring

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination